For the past decade, fusion, cage or not, has been the gold standard in spine surgery. Now, a handful of companies, including Seattle-based Spinal Dynamics, is betting that fusion will be replaced by joint replacement, in this case artificial disc replacement, in spine surgery just as it did in total hip and knee surgery many years ago. Spinal Dynamics' main challenge lies in overcoming surgeon skepticism, especially in cervical procedures where fusions are common and very successful. And to help, they've lined up a distribution agreement with spine market leader Medtronic Sofamor Danek.
by David Cassak
As we noted last month, spine instruments and implants are the orthopedic industry's version of a 20-year overnight success. Today,...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.
CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.
A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
